What 503A pharmacy compounding means
Jillian Foglesong Stabile, MD
Board-certified Family Medicine · Diplomate, ABOM · Reviewed Jun 20, 2026
You filled out an intake form, a clinician signed off, and somewhere in the fine print you saw the word “compounded.” Then the questions started. Is this a knockoff? Is it legal? Is it safe? If you have been searching for plain answers and finding mostly opinions, this is the page that walks you through it, step by step, in language a careful reader can actually use.
The short answer
A 503A compounding pharmacy prepares medication to fill one specific prescription for one specific patient. It is a long-standing, regulated part of US pharmacy practice. It is not a generic, and it is not a brand-name drug. It is a separate path with its own rules.
What you will learn
- What compounding actually is, and the difference between a 503A pharmacy and a 503B outsourcing facility
- Why the patient-specific prescription requirement is the heart of how 503A works
- Who regulates compounding and where the oversight comes from
- What the FDA’s 2026 GLP-1 proposal does, what it does not touch, and why that distinction matters
- The exact questions to ask before you accept any compounded medication
Chapter 01 · The basics
What compounding actually is
Compounding is the practice of preparing a medication to match a written prescription. A licensed pharmacist combines, mixes, or alters ingredients to make a drug for a particular patient. It is one of the oldest parts of pharmacy. Before mass-produced pills, nearly every medication was compounded by hand.
It still has a clear role today. Some patients cannot swallow a tablet and need a liquid. Some are allergic to a dye or filler in the commercial product. Some need a strength that is not sold off the shelf. In each case a clinician writes a prescription that asks for something the standard, mass-produced product does not provide, and a pharmacy prepares it.
Compounding starts with a prescription written for you. It is not a product sitting on a shelf waiting for a buyer. It is made to order.
Chapter 02 · Two pathways
503A and 503B: two paths, two sets of rules
US compounding splits into two legal categories, named after sections of the Federal Food, Drug, and Cosmetic Act. The names sound bureaucratic, but the difference is straightforward once you see it.1, 2
| 503A Pharmacy | 503B Outsourcing Facility | |
|---|---|---|
| Who it serves | One patient, one prescription at a time | Hospitals and clinics; large-batch supply |
| Prescription required? | Yes, for every preparation | Not required per unit for batch production |
| Primary oversight | State board of pharmacy; USP standards | FDA-registered; CGMP manufacturing standards |
| Scale | Patient-specific, not mass production | Bulk batches for in-office use |
Swipe to see the full table on a phone.
A 503A pharmacy compounds medication for an individual patient based on a prescription written for that patient. It is licensed and overseen by its state board of pharmacy and follows standards published by the United States Pharmacopeia (USP). It is not built to mass-produce. It fills prescriptions, one patient at a time.
A 503B outsourcing facility can make medication in large batches without a prescription for each patient, and sell those batches to hospitals and clinics for in-office use. A 503B facility registers with the FDA and must follow Current Good Manufacturing Practice (CGMP) rules. It can also fill patient-specific prescriptions, but its defining feature is batch production.
The simplest way to keep them apart: 503A is made for one person from a prescription. 503B is made in bulk and regulated more like a small manufacturer.
Chapter 03 · The requirement
Why the patient-specific prescription matters
This is the part most explainers skip, and it is the part that answers the “is this legitimate” question.
A 503A pharmacy cannot legally compound medication for the general public the way a factory stamps out pills. The law ties each preparation to a prescription for an identified patient. That requirement is not a formality. It is the line that separates legitimate compounding from mass manufacturing that skips FDA approval.
Because the medication is tied to your prescription, a clinician has to make a clinical decision first. Someone has to review your information, decide the medication is appropriate for you, and write the order. The pharmacy then prepares it to match. The medication exists because a licensed clinician decided it fit your case, not because it was already made and needed a buyer.
That is also why “compounded” is not a synonym for “cheaper version of the brand.” The brand-name product went through the FDA’s full approval process as a finished drug. A compounded preparation has not. It is a distinct preparation, made under a different rule, for a specific person. Lower cost alone is not a qualifying clinical reason for compounding.
A compounded preparation is not FDA-approved and is not equivalent to a brand-name drug. It is a separate, made-to-order preparation under a different legal framework.
Chapter 04 · Who is watching
Safety and oversight: the real framework
A fair question: if compounded medication is not FDA-approved as a finished product, who makes sure it is made correctly?
For 503A pharmacies, oversight runs through several layers. State boards of pharmacy license the pharmacy and the pharmacists, inspect facilities, and can suspend or revoke a license. The USP publishes detailed standards for how sterile and non-sterile preparations must be made, including chapters on sterile compounding that govern cleanrooms, testing, and handling. Pharmacies are expected to follow them. The FDA also retains authority over compounding under federal law and can act against pharmacies that operate outside the rules.2, 3
None of this makes a compounded preparation identical to an FDA-approved drug. It is not, and a careful patient should understand that. A compounded medication has not gone through the FDA’s review of a finished product for safety, effectiveness, and manufacturing consistency the way an approved drug has. What oversight does provide is a real framework of licensing, standards, and inspection that a legitimate pharmacy operates inside.
The honest summary
Quality depends heavily on the specific pharmacy. A licensed, well-run 503A pharmacy that follows USP standards is a very different operation from an unlicensed seller shipping vials with no prescription and no oversight. The category is legitimate. The individual source still matters.
Chapter 05 · The 2026 news
What is changing in 2026, and what is not
This is the news that has people worried, so let us be precise about it.
On May 1, 2026, the FDA published a Federal Register notice proposing not to add semaglutide, tirzepatide, and liraglutide to the 503B bulks list. The 503B bulks list is the set of bulk drug substances that 503B outsourcing facilities are allowed to use when they compound in large batches. The FDA said it did not find sufficient evidence of a clinical need to include these GLP-1 substances on that list. The public comment period on the proposal closes June 30, 2026.4
Here is the part that gets misreported. This proposal is about the 503B bulks list. It governs large-batch outsourcing facilities. It does not change the legal framework for 503A patient-specific compounding. 503A pharmacies operate under a separate section of the law and compound from individual prescriptions under state board oversight. They do not rely on the 503B bulks list to do their work, so the proposed exclusion has no direct legal effect on patient-specific 503A compounding. Multiple health-law analyses of the proposal make the same point.
There is a separate, earlier piece of context worth knowing so you have the full picture. When the FDA’s shortage listing for semaglutide and tirzepatide ended in 2025, that removed the basis that had let pharmacies broadly compound copies of those products during the shortage. Under section 503A, a pharmacy cannot regularly compound something that is essentially a copy of an available commercial drug. So 503A compounding of these medications is appropriate where a clinician documents an individualized medical reason for it, not as a routine stand-in for the brand. That is a clinical judgment your prescriber makes, and it is exactly why the prescription has to come first.5
The 2026 proposal is aimed at one specific path: large-batch 503B production. It does not end or change the patient-specific 503A model. When you read headlines that say “FDA moves to end compounded GLP-1s,” that distinction is the part most headlines miss.
Chapter 06 · Your checklist
What to ask before you accept a compounded medication
You do not need a pharmacy degree to protect yourself. A few direct questions tell you most of what you need to know.
- Is there a real prescription written for me by a licensed clinician? There should be. If a seller offers compounded medication with no clinician review, that is a red flag.
- Is the pharmacy licensed, and in which state? A legitimate 503A pharmacy will tell you. You can confirm a license with the state board of pharmacy.
- Does the pharmacy follow USP standards for sterile preparations? For an injectable, this matters a great deal.
- Who do I contact if something seems wrong with my medication? A real operation has a clinical and pharmacy point of contact, not just a checkout page.
- Is anyone available after I start, not just at the sale? Ongoing support is a fair thing to expect, and its absence tells you something.
If a source cannot answer these plainly, that is your answer.
Some telehealth platforms work only with licensed US 503A pharmacies and keep a clinician involved before and after the prescription. sipra is built that way, with patient-specific 503A compounding through licensed US pharmacies and follow-up that does not stop at checkout. (Individual results vary; compounded medication is prepared to fill a specific prescription and is not an FDA-approved finished product. This article is educational and does not constitute medical advice. A licensed clinician determines whether any medication is appropriate for your situation.)
Three steps to move forward with confidence
Compounding is not a loophole and it is not a knockoff. It is a regulated, patient-specific pathway with its own rules and its own oversight. The questions above are the right ones to ask.
- Confirm the basics. Ask whether a licensed clinician wrote your prescription and whether the pharmacy is licensed in a US state.
- Ask about standards and support. USP compliance for sterile preparations, and a real point of contact after you start, not just at the sale.
- Keep the clinical decision with a clinician. A compounded medication should follow a clinician's judgment that it fits your situation, documented in your prescription.
Know what you are taking, and why.
Lose weight with a plan made just for you
- Same-day doctor visits and prescriptions
- Semaglutide, tirzepatide & other GLP-1s
- FSA & HSA eligible with all plans
From$79/mo
+ Sipra membership*
*Price includes medication only. Active $99/mo Sipra membership required.
Frequently asked questions
Sources
- U.S. Food and Drug Administration. "Compounding and the FDA: Questions and Answers" (503A versus 503B framework). Accessed June 2026. fda.gov
- U.S. Food and Drug Administration. "Compounding Laws and Policies." Accessed June 2026. fda.gov
- United States Pharmacopeia. "USP General Chapter <797> Pharmaceutical Compounding, Sterile Preparations." Accessed June 2026. usp.org
- U.S. Food and Drug Administration. "FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List." April 30, 2026. fda.gov
- U.S. Food and Drug Administration. "GLP-1 Shortage Update" (semaglutide and tirzepatide shortages resolved 2024-2025). Accessed June 2026. fda.gov
Medically reviewed by
Jillian Foglesong Stabile, MD, FAAFP, DABOM
Was this helpful?
Keep reading
Weight LossGLP-1 weight loss 101: how semaglutide and tirzepatide actually work
17 min read
Weight LossHow GLP-1 Treatment With sipra Works, Step by Step
16 min read
Weight LossThe Real Cost of GLP-1 Medication: Every Number Before Your Card Is Charged
16 min read
Weight LossBranded vs compounded GLP-1s: the real difference in 2026
9 min read
Weight LossGLP-1 Myths That Won't Die (and the Facts That Beat Them)
9 min read
Weight LossGLP-1 Side Effects and How to Manage Them, Week by Week
10 min read
Weight LossHow GLP-1s work in the body: the science of appetite and satiety
9 min read
Weight LossWho Should Not Take a GLP-1? Contraindications a Physician Screens For
9 min read